-transparent.png){kind=logo}
We hypothesized that the dehydroepiandrosterone-sulfate (DHEA-S)/cortisol ratio, which has been used as an index of adrenocortical function, would be altered in panic disorder patients and would change after treatment. We evaluated 10 male and 14 female outpatients meeting DSM-III-R criteria for panic disorder. Of these 24 subjects, 13 were treated with clonazepam, 8 were treated with alprazolam, and 3 were treated with placebo as part of a double-blind study. The DHEA-S/cortisol ratio values in the 24 patients with panic disorder (mean = 20.5, SD = 11.6) were significantly higher than those of a group of 60 normal controls (mean = 11.5, SD = 6.01) and were also significantly higher than those of a group of 22 depressed patients (mean = 10.6, SD = 6.33). Although there was no significant difference in the pretreatment DHEA-S/cortisol ratio values between male (mean = 23.6, SD = 11.8) and female (mean = 18.2, SD = 11.3) panic disorder patients, the effects of treatment on this ratio differed between the two sexes. In fact, in the female patients there was a significant decrease in the DHEA-S/cortisol ratio at the end of the study (mean = 15.1, SD = 7.9), while in the male patients there was no significant change in this ratio at the end of the study (mean = 30.2, SD = 21.4). No significant differences were noted between pretreatment and posttreatment DHEA-S/cortisol ratio values in patients treated with alprazolam (n = 8), in patients treated with clonazepam (n = 13), or in patients treated with placebo (n = 3).(ABSTRACT TRUNCATED AT 250 WORDS)
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
August 2017,
Critical care (London, England),
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
January 2021,
Neuropsychobiology,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
March 2008,
Obstetrics and gynecology,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
May 2001,
Critical care medicine,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
March 2013,
Psychoneuroendocrinology,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
April 2006,
Biological psychiatry,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
January 2019,
Journal of clinical psychopharmacology,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
April 1990,
Biological psychiatry,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
October 2023,
Journal of medicine and life,
M Fava, and
J F Rosenbaum, and
R A MacLaughlin, and
G E Tesar, and
M H Pollack, and
L S Cohen, and
M Hirsch
August 2004,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
